Page last updated: 2024-08-18

thiophenes and Dyslipidemia

thiophenes has been researched along with Dyslipidemia in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's5 (83.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hanefeld, M; Herz, M; Lincoff, AM; Malmberg, K; Meyer-Reigner, S; Mudie, N; Ruilope, L; Viberti, G; Wieczorek Kirk, D1
Kohli, A; Kottilil, S; Masur, H; Meissner, EG; Osinusi, A; Remaley, AT; Sampson, M; Sidharthan, S; Tang, L; Townsend, K1
Bhat, S; Greenwood, J; Harriman, G; Harwood, HJ; Huang, X; Kapeller, R; Paul, D; Saha, AK; Tong, L; Wang, R; Westlin, WF1
Bénardeau, A; Benz, J; Binggeli, A; Blum, D; Boehringer, M; Grether, U; Hilpert, H; Kuhn, B; Märki, HP; Meyer, M; Mohr, P; Püntener, K; Raab, S; Ruf, A; Schlatter, D1
Wilding, JP1
Geeraert, B; Geloen, A; Helin, L; Holvoet, P; Malaud, E; Marguerie, G1

Reviews

1 review(s) available for thiophenes and Dyslipidemia

ArticleYear
PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
    Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:11

    Topics: Blood Glucose; Cardiovascular Diseases; Clinical Trials, Phase II as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; Humans; Hypoglycemic Agents; Oxazoles; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones; Thiophenes; Treatment Outcome

2012

Trials

2 trial(s) available for thiophenes and Dyslipidemia

ArticleYear
Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study.
    BMC nephrology, 2014, Nov-18, Volume: 15

    Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Dyslipidemias; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Kidney; Male; Middle Aged; Oxazoles; Pioglitazone; PPAR alpha; PPAR gamma; Renal Insufficiency, Chronic; Therapeutic Equivalency; Thiazolidinediones; Thiophenes

2014
Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration.
    AIDS research and human retroviruses, 2016, Volume: 32, Issue:5

    Topics: Antiviral Agents; Benzimidazoles; Cardiovascular Diseases; Cholesterol, LDL; Coinfection; Drug Therapy, Combination; Dyslipidemias; Female; Fluorenes; Furans; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Quinolines; Ribavirin; Sofosbuvir; Thiophenes; Uridine Monophosphate

2016

Other Studies

3 other study(ies) available for thiophenes and Dyslipidemia

ArticleYear
Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats.
    Proceedings of the National Academy of Sciences of the United States of America, 2016, Mar-29, Volume: 113, Issue:13

    Topics: Acetyl-CoA Carboxylase; Animals; Dyslipidemias; Enzyme Inhibitors; Fatty Liver; Female; Hep G2 Cells; Humans; Insulin Resistance; Male; Molecular Docking Simulation; Obesity; Protein Multimerization; Pyrimidinones; Rats, Sprague-Dawley; Rats, Zucker; Structure-Activity Relationship; Thiophenes

2016
Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes.
    Bioorganic & medicinal chemistry letters, 2009, May-01, Volume: 19, Issue:9

    Topics: Animals; Chemistry, Pharmaceutical; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Drug Design; Dyslipidemias; Humans; Inhibitory Concentration 50; Ligands; Models, Chemical; Molecular Structure; Oxazoles; PPAR alpha; PPAR gamma; Receptors, Cytoplasmic and Nuclear; Thiophenes

2009
CD36 inhibitors reduce postprandial hypertriglyceridemia and protect against diabetic dyslipidemia and atherosclerosis.
    PloS one, 2012, Volume: 7, Issue:5

    Topics: Animals; Atherosclerosis; Benzimidazoles; CD36 Antigens; Cell Line; Diabetes Complications; Disease Models, Animal; Dyslipidemias; Humans; Hypertriglyceridemia; Insulin Resistance; Male; Mice; Postprandial Period; Rats; Rats, Wistar; Thiophenes

2012